8-K filing — VOLITIONRX LTD (VNRX)
Filed: 2026-09-02 AccNo: 0001477932-26-005359 Size: 172 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
VolitionRX shares are trading lower after the company filed a prospectus for an offering of 10 million shares.
Volitionrx Files Prospectus For Offering 10M Common Shares On Behalf Of Selling Shareholders
SEC.
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change Agents down 29%, and Xiao-I down 21%.